We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

58 hedge funds and large institutions have $270M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
58
Holders Change
+58
Holders Change %
–
% of All Funds
1.44%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
58
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$85.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$33.5M
3
RG
Redmile Group
California
+$23.6M
4
PI
Pharmstandard International
Luxembourg
+$14M
5
OFM
Omega Fund Management
Massachusetts
+$12.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$82.4M +$85.7M +4,046,316 New
Wellington Management Group
2
Wellington Management Group
Massachusetts
$34.8M +$33.5M +1,583,185 New
RG
3
Redmile Group
California
$22.5M +$23.6M +1,114,160 New
PI
4
Pharmstandard International
Luxembourg
$14.6M +$14M +662,063 New
OFM
5
Omega Fund Management
Massachusetts
$12.7M +$12.3M +579,650 New
PHS
6
PFM Health Sciences
California
$11M +$10.6M +498,714 New
DM
7
Deerfield Management
New York
$10.3M +$9.93M +468,867 New
CAM
8
Cormorant Asset Management
Massachusetts
$9.56M +$9.22M +434,976 New
AG
9
Artal Group
Luxembourg
$6.6M +$6.36M +300,000 New
Millennium Management
10
Millennium Management
New York
$6.46M +$6.23M +293,862 New
Brown Advisory
11
Brown Advisory
Maryland
$6.31M +$6.08M +287,105 New
BlackRock
12
BlackRock
New York
$5.79M +$5.57M +263,090 New
EC
13
EcoR1 Capital
California
$5.68M +$5.48M +258,457 New
HIM
14
Hillhouse Investment Management
Cayman Islands
$3.75M +$3.61M +170,300 New
Ameriprise
15
Ameriprise
Minnesota
$3.55M +$3.42M +161,474 New
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
$3.02M +$2.91M +137,556 New
CC
17
Casdin Capital
New York
$2.86M +$2.75M +130,000 New
UBS AM
18
UBS AM
Illinois
$2.76M +$2.66M +125,560 New
FCMI
19
Foresite Capital Management II
California
$2.64M +$2.54M +119,912 New
Vanguard Group
20
Vanguard Group
Pennsylvania
$2.51M +$2.41M +113,964 New
JP Morgan Chase
21
JP Morgan Chase
New York
$2.35M +$2.27M +107,078 New
BBA
22
Baker Bros. Advisors
New York
$2.2M +$2.12M +100,000 New
Tudor Investment Corp
23
Tudor Investment Corp
Connecticut
$2.2M +$2.12M +100,000 New
FCMI
24
Foresite Capital Management III
California
$2.01M +$1.94M +91,600 New
Geode Capital Management
25
Geode Capital Management
Massachusetts
$1.57M +$1.52M +71,568 New
1
2 3

JNCE Hedge Fund Activity: Q1 2017 in Review

58 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2017, worth a combined $270M.

Buyers outnumbered sellers: 58 funds opened new JNCE positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $85.7M.

  • 58 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2017, up from 0 in Q4 2016.
  • Funds reported $270M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2017.
  • 58 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2017 and 0 closed out, a net change of +58 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2017 was Fidelity Investments, an estimated $85.7M added.

Based on aggregated 13F filings for Q1 2017.